Biopharma Job Market Recovery Expected by Late 2026 Despite Current Downturn
核心洞察
Industry experts predict the biopharma job market will begin recovering in late 2026, despite over 57% of professionals expecting the turnaround to occur no earlier than 2027.
Biopharma hiring activity remains down 32% year-over-year in October 2025, with over 41,000 employees laid off or projected to be cut through October this year.
Early recovery signals include increased M&A activity with major deals totaling billions, October funding reaching $8.5 billion (up 87% year-over-year), and emerging opportunities in cell therapy, immunology, and radiopharma sectors.
The biopharma job market is poised for recovery by late 2026, according to industry experts, despite widespread pessimism among professionals who don't expect improvement until 2027 or later. This prediction comes as the sector continues to grapple with significant workforce reductions and declining hiring activity.
Current Market Challenges
Biopharma hiring activity remains severely depressed, with 32% fewer average job postings live in October 2025 compared to October 2024, according to BioSpace data. However, there was a 4% month-over-month increase in October, marking the first such rise since May.
The human toll of the downturn is substantial. Through October 2025, over 180 companies have eliminated or projected cuts of more than 41,000 employees. Major reductions include Novo Nordisk's announcement to cut approximately 9,000 employees globally, Merck (搜索)'s projection of 6,000 layoffs as part of a multiyear process, and Bayer's elimination of roughly 1,000 positions during the third quarter.
Expert Predictions and Recovery Timeline
Despite the challenging landscape, two industry experts believe improvement should begin in late 2026. Audrey Greenberg, venture partner and chair at Mayo, and Ira Leiderman, healthcare managing director at investment banking firm Cassel Salpeter & Co. (搜索), both see earlier recovery than the majority of industry professionals.
"Sentiment tends to overshoot on the way down," Greenberg explained. "The fundamentals suggest improvement earlier than that, but the perception lags the data."
A BioSpace LinkedIn poll revealed that 57% of respondents don't expect market recovery until at least 2027, up from 44% in May. Only 7% believe a turnaround could happen by the end of 2025, down from 27% earlier this year.
Early Recovery Signals
Several positive indicators suggest the foundation for recovery is being laid. October 2025 was particularly strong for biopharma financing, with total funding reaching $8.5 billion—up 87% year-over-year and 27% month-over-month, representing the highest monthly total since November 2021.
Merger and acquisition activity has also shown strength, with the third quarter featuring some of the year's highest-value biopharma acquisitions. Notable deals include Merck (搜索)'s $10 billion acquisition of Verona Pharma, Genmab's $8 billion purchase of Merus, and Pfizer's $10 billion acquisition of Metsera.
The FDA approved 35 novel drugs this year, another positive signal according to Greenberg, though regulatory challenges persist. Leiderman noted that FDA upheaval, where more than 3,500 employees lost their jobs, has affected drug approvals, with the agency missing several target decision dates including those for Novavax's next-generation COVID-19 (搜索) vaccine and GSK's chronic obstructive pulmonary disease (搜索) expansion for Nucala.
Structural Changes Driving Recovery
Three key structural changes are expected to accelerate the job market turnaround:
AI-Enabled Regulatory Modernization: FDA pilots in digital twins and model validation are expected to shorten approval timelines, directly driving hiring needs.
Biomanufacturing Reshoring: This trend is creating new employment opportunities in chemistry, manufacturing and controls (CMC), engineering, and quality control.
Health-Economic Discipline: Companies demonstrating real-world value and cost-effectiveness early are attracting both capital and talent.
"The ability to link clinical outcomes to system impact has become a strategic advantage—both for investors deciding where to place bets and for executives deciding where to hire," Greenberg said.
Sector-Specific Recovery Patterns
The recovery is expected to follow a two-speed pattern. Growth in cell and gene therapy, immunology, and radiopharma should emerge by late 2026, while earlier-stage platform companies may remain cautious into 2027.
Greenberg noted that healthspan biotech—the convergence of regenerative medicine, metabolic science, and prevention—is "quietly leading the next cycle." Longevity-focused startups attracted fresh capital in 2025 while broader biotech venture funding slowed.
Hiring will likely return in waves, beginning with manufacturing, analytics, and regulatory roles, followed later by R&D and platform expansion once capital flows fully normalize.
Strategic Advice for Professionals
Rather than leaving the industry, experts recommend pivoting within biopharma. Greenberg identified durable opportunities in regulatory science, CMC, quality, pharmacovigilance, market access, and data-rich functions like bioinformatics and AI analytics.
"If your expertise can translate into one of those domains, there's no reason to leave," she said. "The only people at risk are those unwilling to adapt their skills to how this industry is evolving."
The convergence of AI, policy, and health economics is creating demand for professionals who understand science, data, and reimbursement. "That's where the next wave of jobs will come from, and it's why this transition period, though uncomfortable, is actually laying the groundwork for a smarter, more durable industry," Greenberg explained.
For those seeking immediate opportunities, Massachusetts offers some hope, with tax incentive awards totaling $17.3 million expected to create 806 life sciences jobs in the state this year, including positions at AbbVie (搜索), Eyepoint (搜索), and Genezen (搜索).